Carvolix SA (EPA:CVX)
France · Delayed Price · Currency is EUR 5.64
-0.14 (-2.42%)
Oct 5, 2026, 5:35 PM CET
Carvolix Revenue
Carvolix had revenue of 1.27M EUR in the half year ending June 30, 2026, with 91.68% growth. This brings the company's revenue in the last twelve months to 1.59M, down -83.06% year-over-year. In the year 2025, Carvolix had annual revenue of 900.00K, down -90.49%.
Revenue (ttm)
1.59M
Revenue Growth
-83.06%
P/S Ratio
210.15
Revenue / Employee
26.95K
Employees
59
Market Cap
334.13M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 900.00K | -8.57M | -90.49% |
| Dec 31, 2024 | 9.47M | 5.51M | 138.96% |
| Dec 31, 2023 | 3.96M | 2.62M | 195.91% |
| Dec 31, 2022 | 1.34M | -112.00K | -7.72% |
| Dec 31, 2021 | 1.45M | 627.00K | 76.09% |
| Dec 31, 2020 | 824.00K | -605.00K | -42.34% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Guerbet | 790.65M |
| Eurobio Scientific Société anonyme | 172.26M |
| Biosynex | 95.19M |
| Diagnostic Medical Systems | 51.41M |
| Novacyt | 25.31M |
| Median Technologies | 23.47M |
| Implanet | 13.80M |
| Mauna Kea Technologies | 8.91M |